Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.
about
Miscarriage following dengue virus 3 infection in the first six weeks of pregnancy of a dengue virus-naive traveller returning from Bali to Italy, April 2016Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin AmericaMosquito Exposure and Chikungunya and Dengue Infection among Travelers during the Chikungunya Outbreak in the AmericasDengue: knowledge gaps, unmet needs, and research prioritiesTransmission of Zika virus through breast milk and other breastfeeding-related bodily-fluids: A systematic reviewZika virus-like particle (VLP) based vaccineAssessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East AsiaImmunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.Antibody-based assay discriminates Zika virus infection from other flaviviruses.Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis.Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.Seroprevalence of dengue among healthy adults in a rural community in Southern Malaysia: a pilot study.Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).Dengue virus serotype distribution based on serological evidence in pediatric urban population in IndonesiaBaseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of for Arboviral Disease Control
P2860
Q27468903-0FBD231C-14D3-4979-B7AF-9ACBC07349F9Q27468944-F941E91D-702C-4C7F-A637-8BBFFAAB4565Q28581497-7388A36F-157F-468E-B5C0-A383CFE33997Q28729764-AB536C5D-DE57-4337-A65C-50B1B3331D87Q29353536-CA5A79B3-A695-42F6-AF09-2480A358EF87Q30145640-2D9E65B6-B55B-4E07-80D4-A23FFA4E8D5DQ33723518-D0EA5533-716A-4945-A592-BC309AE8AD04Q35856554-A615F97A-DDBD-4F9F-991B-F80AA1A48F83Q37372595-1109BDD8-926A-4BFB-89F8-8C8C830E99D7Q38157718-5C8EFD45-F147-467C-A39B-C51ADDF0CF53Q38616705-793732B2-9A20-408B-9477-0AB90BF68EBBQ38734455-FEE04871-049D-4583-938B-F0806CD7D355Q40045875-7FA25DC4-02CA-4226-A686-5FD4D9E91D33Q40124689-7A180F98-2EA4-4FDD-9266-C78A98306951Q41926510-1ADDE367-AE96-4398-83DD-1B2AD8850878Q47553469-BCD87D54-1CFE-4B10-A59E-F6F5AA28E614Q47555963-CF0FDD96-17C0-4E51-BFD4-F2182E742000Q55046089-F37488E1-AF34-42A4-A2A1-A4A91891963EQ56476041-65140A9C-EFCC-485D-8C4D-F812321BA2ACQ59137507-053A9916-4CB4-4FC8-91D7-363CE596F60E
P2860
Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Optimization and validation of ...... of dengue vaccine development.
@en
type
label
Optimization and validation of ...... of dengue vaccine development.
@en
prefLabel
Optimization and validation of ...... of dengue vaccine development.
@en
P2093
P2860
P356
P1476
Optimization and validation of ...... of dengue vaccine development.
@en
P2093
Branda T Hu
Matthew I Bonaparte
Rebecca Zedar
Stephen W Hildreth
Tatyana M Timiryasova
P2860
P304
P356
10.4269/AJTMH.12-0461
P407
P577
2013-03-04T00:00:00Z